Market Cap 447.62B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 24.86
Forward PE 17.75
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 6,999,405
Avg Vol 7,321,322
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 96%
Beta 0.32
Analysts Strong Sell
Price Target $250.97

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
CapitalLogic1
CapitalLogic1 Jun. 30 at 10:17 PM
Jefferies upgraded $ABVX to Buy from Hold, raising its price target to $158 from $108. The firm cited “we’re back” sentiment, stating that key overhangs have been removed and strong clinical data should help drive value realization going forward. Jefferies also highlighted broader implications across the biotech space, referencing multiple peers including $ABBV, MRK, and others, suggesting a more constructive sector backdrop following recent updates.
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 30 at 10:15 PM
$SLS VIALE-M Phase 3 trial conducted by $ABBV for Remission Maintenance FAILED --- and not a 1 dimensional dosing regime. There were 7 different dosing Cohorts - The SAP was modified 7 times, attempting to find a dose uL amount with every combination of Injection / Intravenous and All Oral - None Work. VIALE-T Post Transplant Maintenance Phase 3 ALSO FAILED VERONA - High Risk MDS/ AML Precursor - also FAILED Meanwhile we are Seeing Miraculous ALL Pooled Survival in the SLS REGAL Phase 3 - Gps and Control on Aza VEN. Dr.s Treating the actual Patients are also on record - BAT is Toxic, Survival is not durable, extremely poor. Smart Money Knows its Gps doing what its done in all Previous Trials, Prevent Relapse and Extend Survival, with increased OS directly correlated to OS - including in 2 Phase 2 For AML REMISSION MAINTENANCE Trials. it is not complicated. buy and hold for the gold
0 · Reply
Blockwave1
Blockwave1 Jun. 30 at 9:16 PM
$ABBV 🌊 $260 02 JUL 26 (W) CALL 100 $0.68 ➡️ $1.40 🤑 105% GAINER! ☢️ TURN MY POST NOTIFICATIONS ON! 🚨
0 · Reply
ApexEquityVault
ApexEquityVault Jun. 30 at 9:13 PM
$ABBV 🩺 $260 02 JUL 26 (W) CALL 100 $0.68 ➡️ $1.40 🤑 105% GAINER! ☢️ TURN MY POST NOTIFICATIONS ON!
0 · Reply
ApexEquityVault
ApexEquityVault Jun. 30 at 9:11 PM
$ABBV 🩺 $255 02 JUL 26 (W) CALL 100 $0.43 ➡️ $3.50 🤑 713% GAINER! ☢️ TURN MY POST NOTIFICATIONS ON!
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 30 at 8:47 PM
$SLS $ABBV $BMY Vetoclax will become Obsolete after GPS FDA/EMA approval. AbbVie will be the biggest looser if another big pharmaceutical BO Sellas. 2nd biggest looser will be Onureg Bristol-Myers Squibb Co. ✌️🙏❤️‍🩹
0 · Reply
Quantumup
Quantumup Jun. 30 at 8:24 PM
Jefferies⬆️ $ABVX to Buy-$158 from Hold-$108 and said, We're Back: Overhang Removed, Strong Data Should Drive Value, Upgrade to BUY. CRVS SYRE PTGX - JNJ ABGE - $ABBV PALI RHHBY TEVA MRK Here's what else Jefferies had to say: https://x.com/Quantumup1/status/2072052823697801726?s=20
0 · Reply
KryptonResearch
KryptonResearch Jun. 30 at 6:47 PM
While markets are extremely focused on the inputs to the AI trade (and for good reason, as this is where the capital is flowing at the present moment). We take a look at the flip side of the AI trade. Those using AI to accelerate their businesses. Today’s investment is one of our favorites. A great business and revolutionary technology, but more importantly, one that is going to transform the lives of billions. $LLY $NVO $ABBV $PFE $JNJ Take a read: https://kryptonresearch.substack.com/p/blood-money
0 · Reply
SmartCapitall
SmartCapitall Jun. 30 at 6:09 PM
$ABBV and Genmab highlight Epkinly combo results after monotherapy failure, with the Epcore DLBCL-4 trial showing a positive signal in DLBCL. The read-through is lifting expectations into the upcoming and more critical DLBCL-2 first-line data readout. Still early-stage oncology narrative, but improving sentiment around combo strategy vs single-agent limitations.
0 · Reply
kindness123
kindness123 Jun. 30 at 5:34 PM
$ABBV $LLY $MRK https://finance.yahoo.com/healthcare/articles/merck-abbvie-probed-us-lawmakers-161900980.html
0 · Reply
Latest News on ABBV
AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 26, 2026, 8:00 AM EDT - 4 days ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call


AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 6 days ago

AbbVie's $11 Billion Immunology Bet

APGE


Apogee Therapeutics moved to No Rating at BofA

2026-06-23T11:29:50.000Z - 7 days ago

Apogee Therapeutics moved to No Rating at BofA

APGE


AbbVie price target raised to $273 from $265 at Canaccord

2026-06-23T11:04:51.000Z - 7 days ago

AbbVie price target raised to $273 from $265 at Canaccord

APGE


AbbVie announces European Commission approval for Skyrizi

2026-06-23T10:24:35.000Z - 7 days ago

AbbVie announces European Commission approval for Skyrizi


AbbVie announces European Commission approval of Maviret

2026-06-23T10:00:54.000Z - 7 days ago

AbbVie announces European Commission approval of Maviret


AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 8 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE


AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 8 days ago

AbbVie Transcript: M&A announcement


AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 8 days ago

AbbVie Slides: M&A announcement


AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 8 days ago

AbbVie Press release: M&A announcement


AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 8 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE


AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 8 days ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE


AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 12 days ago

AbbVie Declares Quarterly Dividend


US FDA approves AbbVie's rare blood cancer drug

May 27, 2026, 3:33 PM EDT - 4 weeks ago

US FDA approves AbbVie's rare blood cancer drug


AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 7 weeks ago

AbbVie Transcript: AGM 2026


AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings Call Transcript: Q1 2026


AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings release: Q1 2026


AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Quarterly report: Q1 2026


AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 2 months ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth


AbbVie Reports First-Quarter 2026 Financial Results

Apr 29, 2026, 7:47 AM EDT - 2 months ago

AbbVie Reports First-Quarter 2026 Financial Results


US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:19 PM EDT - 2 months ago

US FDA declines to approve AbbVie's wrinkle treatment


CapitalLogic1
CapitalLogic1 Jun. 30 at 10:17 PM
Jefferies upgraded $ABVX to Buy from Hold, raising its price target to $158 from $108. The firm cited “we’re back” sentiment, stating that key overhangs have been removed and strong clinical data should help drive value realization going forward. Jefferies also highlighted broader implications across the biotech space, referencing multiple peers including $ABBV, MRK, and others, suggesting a more constructive sector backdrop following recent updates.
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 30 at 10:15 PM
$SLS VIALE-M Phase 3 trial conducted by $ABBV for Remission Maintenance FAILED --- and not a 1 dimensional dosing regime. There were 7 different dosing Cohorts - The SAP was modified 7 times, attempting to find a dose uL amount with every combination of Injection / Intravenous and All Oral - None Work. VIALE-T Post Transplant Maintenance Phase 3 ALSO FAILED VERONA - High Risk MDS/ AML Precursor - also FAILED Meanwhile we are Seeing Miraculous ALL Pooled Survival in the SLS REGAL Phase 3 - Gps and Control on Aza VEN. Dr.s Treating the actual Patients are also on record - BAT is Toxic, Survival is not durable, extremely poor. Smart Money Knows its Gps doing what its done in all Previous Trials, Prevent Relapse and Extend Survival, with increased OS directly correlated to OS - including in 2 Phase 2 For AML REMISSION MAINTENANCE Trials. it is not complicated. buy and hold for the gold
0 · Reply
Blockwave1
Blockwave1 Jun. 30 at 9:16 PM
$ABBV 🌊 $260 02 JUL 26 (W) CALL 100 $0.68 ➡️ $1.40 🤑 105% GAINER! ☢️ TURN MY POST NOTIFICATIONS ON! 🚨
0 · Reply
ApexEquityVault
ApexEquityVault Jun. 30 at 9:13 PM
$ABBV 🩺 $260 02 JUL 26 (W) CALL 100 $0.68 ➡️ $1.40 🤑 105% GAINER! ☢️ TURN MY POST NOTIFICATIONS ON!
0 · Reply
ApexEquityVault
ApexEquityVault Jun. 30 at 9:11 PM
$ABBV 🩺 $255 02 JUL 26 (W) CALL 100 $0.43 ➡️ $3.50 🤑 713% GAINER! ☢️ TURN MY POST NOTIFICATIONS ON!
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 30 at 8:47 PM
$SLS $ABBV $BMY Vetoclax will become Obsolete after GPS FDA/EMA approval. AbbVie will be the biggest looser if another big pharmaceutical BO Sellas. 2nd biggest looser will be Onureg Bristol-Myers Squibb Co. ✌️🙏❤️‍🩹
0 · Reply
Quantumup
Quantumup Jun. 30 at 8:24 PM
Jefferies⬆️ $ABVX to Buy-$158 from Hold-$108 and said, We're Back: Overhang Removed, Strong Data Should Drive Value, Upgrade to BUY. CRVS SYRE PTGX - JNJ ABGE - $ABBV PALI RHHBY TEVA MRK Here's what else Jefferies had to say: https://x.com/Quantumup1/status/2072052823697801726?s=20
0 · Reply
KryptonResearch
KryptonResearch Jun. 30 at 6:47 PM
While markets are extremely focused on the inputs to the AI trade (and for good reason, as this is where the capital is flowing at the present moment). We take a look at the flip side of the AI trade. Those using AI to accelerate their businesses. Today’s investment is one of our favorites. A great business and revolutionary technology, but more importantly, one that is going to transform the lives of billions. $LLY $NVO $ABBV $PFE $JNJ Take a read: https://kryptonresearch.substack.com/p/blood-money
0 · Reply
SmartCapitall
SmartCapitall Jun. 30 at 6:09 PM
$ABBV and Genmab highlight Epkinly combo results after monotherapy failure, with the Epcore DLBCL-4 trial showing a positive signal in DLBCL. The read-through is lifting expectations into the upcoming and more critical DLBCL-2 first-line data readout. Still early-stage oncology narrative, but improving sentiment around combo strategy vs single-agent limitations.
0 · Reply
kindness123
kindness123 Jun. 30 at 5:34 PM
$ABBV $LLY $MRK https://finance.yahoo.com/healthcare/articles/merck-abbvie-probed-us-lawmakers-161900980.html
0 · Reply
NasdaqAlpha
NasdaqAlpha Jun. 30 at 3:57 PM
$ABBV has taken some heat after the recent trial headlines, but I don't think the whole pipeline should be judged on one update. The market tends to swing between optimism and disappointment with biotech, while the longer-term picture usually takes much more time to play out. I'm watching how investors respond after the dust settles rather than reacting to a single headline.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 30 at 3:09 PM
$SLS $GILD $ABBV Great Day to BUY $SLS Been 50 Days since the 78th Event --- 22 Day Per Event Rate 80th EVENT IS NOW TRULY IMMINENT ... ALONG WITH BALLISTIC SHARE PRICE LAUNCH.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 30 at 3:04 PM
$SLS $GILD $ABBV Been 50 Days since the 78th Event --- 22 Day Per Event Rate 80th EVENT IS NOW TRULY IMMINENT ... ALONG WITH BALLISTIC SHARE PRICE LAUNCH. 60th Event / Share Price Launch 72nd Event / Share Price Launch 78th Event / Share Price Launch 80th Event / Share Price Will Be Launching IMMINENTLY. Just Look at the Market Action Since the 60th Event, when the IDMC Unblinded Actual Phase 3 Median Overall Survival and Immune Response Data - from the Ongoing P3. - Share Price 10x, Market Cap +12X Cash on Hand up 10x Runway to 2030, Institutional Funds from 39 to 167 - not 1 Short only. Smarter Money than US Knows Gps is Golden.
0 · Reply
Oldpuck
Oldpuck Jun. 30 at 2:59 PM
$ABBV Rotation didn't last very long
0 · Reply
NasdaqFrontier
NasdaqFrontier Jun. 30 at 2:56 PM
$ABBV is making waves with the latest phase 3 results and aggressive M&A strategy. I wasn't expecting such a steady reaction to the acquisition news, but it seems the market is focused on the long-term pipeline strength. Still, I’m not chasing the current level. Stalking this base to see if it holds support before I even consider adding to the position.
0 · Reply
Blockwave1
Blockwave1 Jun. 30 at 2:44 PM
Telegram channel: https://t.me/BlockWave10 $ABBV $QQQ $SPY $AAPL remembers this guy? 😂🔥 He’s been absolutely crushing the setups! The trust and consistency have been incredible, and I truly appreciate the support. 💯 I’ll keep doing my part and bringing the best opportunities. Much love to everyone who’s been rocking with us! ❤️🌊
0 · Reply
NvidiaKing
NvidiaKing Jun. 30 at 2:02 PM
$ABBV this is a POS 🐓
0 · Reply
Quantumup
Quantumup Jun. 30 at 11:13 AM
Guggenheim reiterated Best Idea $ABVX at Buy-$175 SYRE CRVS PALI PTGX - $JNJ APGE - $ABBV RHHBY MRK TEVA Here's what Guggenheim had to say in its note to investors: https://x.com/Quantumup1/status/2071914563683901822?s=20
0 · Reply
Quantumup
Quantumup Jun. 30 at 10:24 AM
BTIG⬆️ $ABVX-$175,⬆️PoS for obefazimod in UC to 95% & CD to 85% and reiterated at Buy PTGX - $JNJ APGE - $ABBV SYRE PALI RHHBY MRK TEVA Here's what BTIG said in its note to investors: https://x.com/Quantumup1/status/2071902283541999785?s=20
0 · Reply
notreload_ai
notreload_ai Jun. 30 at 9:00 AM
$ABBV, $GMAB new drug combo helps lymphoma patients live longer without worsening disease, cutting risk by ~60%—without chemotherapy. https://notreload.xyz/xy/abbvie-genmab-positive-phase-3-results-in-r-r-dlbcl/
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 30 at 3:55 AM
$SLS $GILD $ABBV r/gabri71 deep cut In conclusions the Authors state ‘The longer OS observed in patients who subsequently underwent allo-HSCT refrains the fact that stem cell transplantation after the achievement of a CR/CRi is still the only viable, and possibly curative, option for patients with r/R AML (and this was around 20 months of mOS after reaching CR2 status)’. 20 month MOS FOR CR2 getting transplant, 8.8 month MOS for CR2 not getting Transplant, on BAT. https://www.reddit.com/r/sellaslifesciences/s/dWtZbCNCoh
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 30 at 3:47 AM
$ABBV $BMY $LLY $PFE $SLS BIG MOVES IN BIOTECH INNOVATION IS MERGING. SLS Next up. ✌️🙏❤️‍🩹
0 · Reply